Huihui Jiang1, Xin Yang2, Miaomiao Mi3, Xiaonan Wei4, Hongyuan Wu1, Yu Xin5, Liping Jiao1, Shengjun Sun6, Chengming Sun7. 1. Qingdao University, Qingdao, 266000, Shandong, China. 2. Department of Laboratory Center, Yantai Yuhuangding Hospital Affiliated to Qingdao University, 20 Yuhuangding East Road, Yantai, 264000, Shandong, China. 3. Department of Laboratory Center, Qilu Hospital of Shandong University, Jinan, 250000, Shandong, China. 4. Department of Laboratory Center, Qingdao Women and Children's Hospital, Qingdao, 266000, Shandong, China. 5. Binzhou Medical University, Yantai, 264000, Shandong, China. 6. Department of Laboratory Center, Yantaishan Hospital, Yantai, 264000, Shandong, China. 7. Department of Laboratory Center, Yantai Yuhuangding Hospital Affiliated to Qingdao University, 20 Yuhuangding East Road, Yantai, 264000, Shandong, China. chengmingsun@163.com.
Abstract
BACKGROUND: PER2 gene methylation is closely related to the occurrence and progress of some cancers, but there is no method to quantitatively detect PER2 methylation in conventional laboratories. So, we established a TaqMan real-time fluorescence quantitative methylation specific PCR (TaqMan real-time FQ-MSP) assay and use it for quantitative detection of PER2 methylation in leukemia patients. METHODS: According to the PER2 sequence searched by GenBank, a CpG sequence enrichment region of the PER2 gene promoter was selected, and the methylated and unmethylated target sequences were designed according to the law of bisulfite conversion of DNA to construct PER2 methylation positive and negative reference materials. Specific primers and probe were designed. The reference materials were continuously diluted into gradient samples by tenfold ratio to evaluate the analytical sensitivity, specificity, accuracy and reproducibility of the method, and the analytical sensitivity of TaqMan real-time FQ-MSP assay was compared with that of the conventional MSP assay. At the same time, the new-established TaqMan real-time FQ-MSP assay and the conventional MSP assay were used to detect the PER2 methylation level of 81 patients with leukemia, and the samples with inconsistent detection results of the two assays were sent to pyromethylation sequencing to evaluate the clinical detection performance. RESULTS: The minimum detection limit of TaqMan real-time FQ-MSP assay for detecting PER2 methylation level established in this study was 6 copies/uL, and the coefficient of variation(CV) of intra-assay and inter-assay was less than 3%. Compared with the conventional MSP assay, it has higher analytical sensitivity. For the samples with inconsistent detection results, the results of pyrosequencing and TaqMan real-time FQ-MSP assay are consistent. CONCLUSION: TaqMan real-time FQ-MSP assay of PER2 methylation established in this study has high detection performance and can be used for the detection of clinical samples.
BACKGROUND: PER2 gene methylation is closely related to the occurrence and progress of some cancers, but there is no method to quantitatively detect PER2 methylation in conventional laboratories. So, we established a TaqMan real-time fluorescence quantitative methylation specific PCR (TaqMan real-time FQ-MSP) assay and use it for quantitative detection of PER2 methylation in leukemia patients. METHODS: According to the PER2 sequence searched by GenBank, a CpG sequence enrichment region of the PER2 gene promoter was selected, and the methylated and unmethylated target sequences were designed according to the law of bisulfite conversion of DNA to construct PER2 methylation positive and negative reference materials. Specific primers and probe were designed. The reference materials were continuously diluted into gradient samples by tenfold ratio to evaluate the analytical sensitivity, specificity, accuracy and reproducibility of the method, and the analytical sensitivity of TaqMan real-time FQ-MSP assay was compared with that of the conventional MSP assay. At the same time, the new-established TaqMan real-time FQ-MSP assay and the conventional MSP assay were used to detect the PER2 methylation level of 81 patients with leukemia, and the samples with inconsistent detection results of the two assays were sent to pyromethylation sequencing to evaluate the clinical detection performance. RESULTS: The minimum detection limit of TaqMan real-time FQ-MSP assay for detecting PER2 methylation level established in this study was 6 copies/uL, and the coefficient of variation(CV) of intra-assay and inter-assay was less than 3%. Compared with the conventional MSP assay, it has higher analytical sensitivity. For the samples with inconsistent detection results, the results of pyrosequencing and TaqMan real-time FQ-MSP assay are consistent. CONCLUSION: TaqMan real-time FQ-MSP assay of PER2 methylation established in this study has high detection performance and can be used for the detection of clinical samples.
Authors: Nils H Thoennissen; Gabriela B Thoennissen; Sam Abbassi; Shayan Nabavi-Nouis; Tim Sauer; Ngan B Doan; Sigal Gery; Carsten Müller-Tidow; Jonathan W Said; H Phillip Koeffler Journal: Leuk Lymphoma Date: 2012-02-21
Authors: Ali Mteyrek; Elisabeth Filipski; Catherine Guettier; Malgorzata Oklejewicz; Gijsbertus T J van der Horst; Alper Okyar; Francis Lévi Journal: Int J Cancer Date: 2017-03-16 Impact factor: 7.396
Authors: Sigal Gery; Adrian F Gombart; William S Yi; Chloe Koeffler; Wolf-K Hofmann; H Phillip Koeffler Journal: Blood Date: 2005-06-28 Impact factor: 22.113